Full Press Release Details
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) --
Company: Skye Bioscience, Inc. (NYSE: SKYE) is a clinical stage biopharmaceutical company that focuses on developing molecules that modulate G protein-coupled receptors (“GPCRs”) to treat obesity, overweight, and metabolic diseases. The Company’s lead product candidate is nimacimab.
What is the class period? November 4, 2024 - October 3, 2025
What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Skye securities during the class period because the Company allegedly misled investors regarding the viability of its lead drug candidate.
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
What are the allegations? According to the complaint, during the class period, defendants failed to disclose that (i) nimacimab was less effective than defendants had led investors to believe and (ii) accordingly, nimacimab’s clinical, regulatory, and commercial prospects were overstated.
Plaintiff alleges that on October 6, 2025, Skye issued a press release “announc[ing] the topline data from its 26-week Phase 2a CBeyond™ proof-of-concept study of nimacimab[.]” The press release disclosed that the “the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo” and that “preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy.” On this news, Skye’s stock price fell $2.85 per share, or 60%, to close at $1.90 per share on October 6, 2025.
What can I do now? You may be eligible to participate in the class action against Skye Biosciences, Inc. Shareholders who wish to serve as lead plaintiff for the class must submit their papers with the court by January 16, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.
Attorney Advertising. Past results do not guarantee a similar outcome.